ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication

Tokyo (JCNN) - Bristrol-Myers Squibb (BMS) and Otsuka Pharmaceutical have jointly announced that the US Food and Drug
Administration (FDA) approved an additional indication for ABILIFY (aripiprazole) Tablets and Oral Solution, atypical
antipsychotics, as of March 1.


With this approval, ABILIFY is now applicable to the maintenance treatment, namely preventing relapses, of bipolar I
disorder. Since its initial approval in 2002, over 3.7 million prescriptions have been written in the US.


In Japan, ABILIFY , for which a new drug application was filed in March 2003, is currently under examination.


View Otsuka Pharmaceutical Co., Ltd. company
profile here


Copyright © 2001-2004 JCNN. All rights reserved. A
division of Japan Corporate News Network KK.


View drug information on Abilify.